According to a recent press release, The University of Texas MD Anderson Cancer Center and Manhattan Scientifics have announced a collaborative agreement in an effort research and develop a new breakthrough technology in cancer treatment. The new technology, which was developed by Edward R. Flynn, PhD, a member of Manhattan Scientifics’ science and technology committee, claims to facilitate the very early detection of cancer. In addition to serving as science and technology committee member, Dr. Flynn is also the founder and chief scientist of MHTX’s subsidiary, Senior Scientific LLC, which is currently working on “commercializing patented non-invasive technology using ultra-sensitive magnetic detectors to locate, identify and measure tumors thousands of times smaller than detectable using current technologies.”
For their part, MD Anderson will test the new system developed by Dr. Flynn and Manhattan Scientifics, bringing to bear MD Anderson’s advanced cancer research facilities and the shared vision of helping commercialize truly practical, effective cancer diagnostics and treatments. Specifically, MD Anderson researcher will help to test the system’s potential to avoid false positives and effectively deliver results on detecting cancer years before traditional methods. given the fact that with many cancers, survival rates are dependent on early detection, this new technology could make a substantial impact on cancer outcomes.
Together with funding from the National Institute of Health, Manhattan Scientific has financed the development and construction of Dr. Flynn’s new medical instrument, which utilizes “iron oxide nanoparticles and biomarkers to target specific cancer cell receptors. The instrument is used to rapidly magnetize, and then detect, the nanoparticles that have found cancer cells. The resulting measurement is specific to the targeted cells and is much more sensitive than existing technologies.” If successful, this new technology could eventually come to replace the use of PET, MRI, CT and X-ray.
This new collaboration between MD Anderson and Manhattan Scientifics is not a new relationship: the two organizations have been working together following two years of informal collaboration. The agreement, however, is the first official, formal collaboration, and is specifically designed to develop enough data on the technology to eventually seek FDA approval. Accord to the press release, “Under the collaboration agreement announced today, Senior Scientific will supply a next generation instrument to MD Anderson during the first quarter of 2014. MD Anderson will be the first institution to use the new technology in its cancer research programs.”
Dr. Flynn said, “Cancer remains the second most common cause of death in the U.S., accounting for nearly one of every four deaths. Our formal collaboration with MD Anderson brings to fruition years of research from our MHTX team. I am excited to reach this important milestone which places our ground breaking technology into the skilled hands of the physicians and researchers at MDACC to help fight Cancer, the emperor of all maladies.”